Table 2. Patient characteristics.
| Characteristic | n (%) |
| Female | 42 (100) |
| Age (years) | 67.0 ± 12.1 |
| Height (cm) | 155.4 ± 8.1 |
| Body weight (kg) | 53.7 ± 10.0 |
| IPAQ | 329.4 ± 559.2 |
| Rheumatoid factor Presence of anti-citrullinated protein autoantibodies |
28 (66.7) 23/39 (59.0) |
| Disease duration (years) Duration ≤2 years |
9.2 ± 10.6 9 (21.4) |
| Past operations | 21 (50) |
| DAS28-ESR Remission Low disease activity Moderate disease activity High disease activity |
2.91 ± 0.91 17 (40.5) 11 (26.2) 13 (31.0) 1 (2.4) |
| Tenderness in joints | 1 (0–3) |
| Swelling in joints | 0 (0–0) |
| ESR (mm/h) | 15.3 ± 12.8 |
| Patient’s general health (VAS, mm) | 35.6 ± 2.39 |
| RAPID3 Remission Low disease activity Moderate disease activity High disease activity |
8.7 ±5.1 8 (19.0) 3 (7.1) 20 (47.6) 11 (26.2) |
| HAQ score HAQ ≤0.5 |
0.69 ±0.62 21 (50.0) |
| DASH | 26.7 ± 20.1 |
| Steinbrocker stage I/II/III/IV | 12 (28.6)/12 (28.6)/12 (28.6)/6 (14.3) |
| Steinbrocker class I/II/III/IV | 6 (14.3)/36 (85.7)/0/0 |
| bDMARDsa/tsDMARDsb/MTX/ other csDMARDS | 19 (45.2)/14 (33.3)/4 (9.5)/5 (11.9) |
| Corticosteroid usec
Corticosteroid dosage (mg/day) |
7 (16.7) 4 ± 1.4 |
| Right handedness | 40 (95.2) |
Data given as number (percentage), mean ± standard deviation, or median (interquartile range).
VAS, Visual Analog Scale.
a bDMRADs monotherapy: 14 and in combination with csDMARDs: 5 (MTX: 3); b tsDMARDs monotherapy: 11 and in combination with csDMRADs: 3 (MTX: 2); c Prednisolone corticosteroid in combination with bDMARDs: 4, tsDMARDs: 2, and csDMARDs: 1.